Our Technology Transfer Support Includes

Dosage Form Development Support

• Respective APIs to Specific Formulation Developments:
  

  • Granules and Sachets: Free-flowing granulated systems with optimised particle distribution, moisture barrier protection, and dispersibility ensuring precise unit-dose delivery.
  • Tablets: Advanced optimisation of direct compression, wet granulation, and dry granulation, achieving superior powder flowability, compressibility, and hardness control.
  • Capsules: Precision-filled hard gelatin or HPMC systems with optimised bulk density, blend homogeneity, and fill weight accuracy, preventing segregation.
  • Pellets: Multiarticulate systems using extrusion-spheronization, powder layering for controlled release, enhanced bioavailability, superior GI targeting.
  • Mouth Spray: Formulating a specific active pharmaceutical ingredient (API) into a localized, metered-dose intraoral spray for rapid transmucosal systemic absorption
  • Serum: Serum API integration maps direct endpoints to decentralized liquidity pools, enabling automated, low-latency programmatic trading and order-book interaction.
  • Cream: Advanced liposomal encapsulation technology facilitates targeted skin deposition, enhanced stability, and sustained release of the active ingredient.
  • Effervescent: The formulation API interfaces with galenical databases, automating stoichiometric calculations for acid-base couples to optimize effervescent disintegration kinetics.
  • Oral Liquid Suspension: The Oral Liquid Suspension API interfaces protocols, automating dosage-to-volume calculations and viscosity-calibrated dispensing workflows for paediatric /geriatric EHR support.
  • Powder Blend Stick Sack: The formulation API interfaces with the Formulation Management System (FMS), optimizing critical parameters like powder flowability and bulk density for stick pack encapsulation.

Advanced Release Systems

• GI-targeted enteric-coated support

  • Strategic GI-bypass delivery utilising delayed-release, pH-responsive, site-specific mechanisms maximising intestinal absorption, minimising gastric degradation.
  • pH-dependent enteric protection using advanced polymer engineering, preventing gastric degradation, protecting liposomal membrane integrity.

• Sustained release controlled systems

  Release-modulated platforms through hydrophilic/hydrophobic polymer matrix engineering, diffusion controlling prolonged therapeutic efficacy.

• Coating system development

  Optimisation of barrier coatings, enteric coatings, sustained-release layers, improving moisture resistance, oxidation control, and release modulation.

Parameter Optimisation & Protocols

• Critical process parameter standardisation

  Scientific standardisation of CPPs and CQAs, including mixing efficiency, granulation endpoint, drying kinetics, and coating uniformity.

• Manufacturing process transfer

  Seamless transfer of validated formulation processes, technology packages, batch manufacturing protocols, standard operating parameters.

• Pilot batch execution support

  Technical supervision of pilot-scale manufacturing trials verifying formulation robustness, process feasibility, and equipment suitability.

• Scale-up commercial validation

  Scientific scale-up execution with validation of process reproducibility, batch-to-batch consistency, in-process controls, and GMP compliance

Precision Scale-Up Protocols

• Sonication Shear rate optimisation
  

  Detailed amplitude and pulse-cycle instructions ensuring uniform particle distribution, preventing hotspots leading to ingredient degradation and high-speed homogenisations defining precise energy input in the nanometer range without over-shearing.

• Temperature control profiles

  Exact cooling curves and phase-addition temperatures required for incorporating heat-sensitive actives without compromising molecular potency.

• Material Characterization & Rheological Profiling

  Establish baseline profiles for bulk density, flowability (Hausner ratio), viscosity, and viscoelasticity under stress to predict how the formulation behaves when moving from benchtop volumes to high-throughput production.

• Material Transfer & Hold-Time Validation

  Define strict protocols for intermediate storage and mechanical transfer (e.g., vacuum conveyance or gravity feed), ensuring phase stability, preventing segregation, and mitigating oxidation or moisture uptake.

Process & Manufacturing Transfer – Quality Control Integration

• Real-time transparency monitoring

  Benchmarks for turbidity and refractive index testing, enabling manufacturing teams to verify batch quality in real time.

• Batch-to-batch consistency protocols

  Defining Critical Quality Attributes, ensuring the first batch is identical to the thousandth batch with no drift in viscosity, pH, porosity, and particle size diffusion verification: Instructions for simplified diffusion models that ensure sustained release, validated in labs and achieved in every production run.

• Equipment material geometry
  

  Optimal tank shapes and contact materials that prevent the adsorption of premium lipids, ensuring maximum yield and cost-efficiency.

• Analytical Method Transfer (AMT) & Co-Validation
  

  Execute formal, protocol-driven transfer of all assay methods between the sending and receiving QC labs, establishing strict acceptance criteria for intermediate precision and robustness.

• In-Process Control (IPC) Threshold Alignment
  

  Establish phase-appropriate IPC limits and sampling plans tailored to the manufacturing scale, ensuring the receiving QC lab can detect real-time drift.

• Stability Protocol Synchronization
  

  Initiate site-transfer stability studies under ICH guidelines using representative commercial-scale batches to confirm that the manufacturing environment and scale-up shear forces do not compromise long-term product integrity.

Product Development Dossier Preparation

• Product Information Support

  Comprehensive scientific data provision, delivering ICH-compliant documentation, multi-compendial specifications, and robust dossiers for frictionless global product commercialization.

• Master Formula Record (MFR) Support 

  Development of GMP-compliant Master Formula Records with validated batch formulas, process instructions, equipment details, in-process controls, and critical manufacturing checkpoints.

  • GMP-compliant formula documentation: Development of validated batch formulas with precise process instructions and equipment details throughout the manufacturing sequence.
  • In-process control checkpoints: Integration of critical manufacturing checkpoints ensuring batch-to-batch consistency and quality assurance.
  • Analytical Development: Comprehensive analytical development support providing robust, compendial method validation, impurity profiling, and stability testing to accelerate regulatory clearance.
  • Process Development: Process Development is the systematic optimization, scale-up, and validation of robust, GMP-compliant manufacturing pathways ensuring product quality, reproducibility, and yield
  • Scale-up & Validation: Seamlessly transitioning from laboratory innovation to commercial reality through precision engineering, robust process validation, and absolute GMP compliance.
  • Comprehensive development traceability: Complete compilation of formulation development history, composition rationale, optimisation studies, analytical findings establishing product evolution.
  • Scientific Justification Documentation: Stability data integration with scientifically structured rationale supporting formulation choices throughout the development lifecycle.
  • End-to-end development records: From initial feasibility through scale-up, capturing all critical development milestones for regulatory submission.

Stability Study Dossier Preparation

Documentation of accelerated, intermediate, and long-term stability protocols with real-time data interpretation, shelf-life justification, and ICH-compliant product stability evaluation.

• Real-Time/Long-Term Stability Studies

  Long-term kinetic evaluations establishing definitive product shelf-life and storage statements under ICH-harmonized climatic zone parameters via rigorous stability-indicating methodologies.

• Accelerated Stability Studies
  

  Predictive kinetic evaluation optimizing ICH Q1A(R2) thermal/hygrometric stress profiles to rapidly elucidate degradation pathways and guarantee long-term shelf-life integrity.

• Intermediate Stability Studies
  

  ICH Q1A(R2)-compliant evaluation at mitigating regulatory risk upon accelerated-phase significant change to validate global shelf-life kinetics.

• Forced Degradation/Stress Testing Studies
  

  Mechanistic degradation profiling via deliberate chemical, thermal, and photolytic stress, validating stability-indicating analytical methods to map structural degradation pathways.

Specification Documentation Support

Development of scientifically justified specifications, Certificates of Analysis (COA), acceptance criteria, test methods, and release standards for raw materials and finished products.

• Specification Master Documents
  

  These documents establish the mandatory numerical limits and analytical criteria that a material must pass.

  • Raw Materials Specification (RMS) : Predefined testing criteria for incoming unrefined chemicals or active ingredients.
  • Excipient Specification: Quality benchmarks for inactive matrix materials, binders, or lipid carriers, aligned with multi-compendial standards (USP/EP/BP/IP).
  • In-Process Specification (IPS): Quality targets enforced during the manufacturing run (e.g., blend uniformity, core tablet hardness, or emulsion droplet size).
  • Finished Product Release Specification: The final criteria a batch must meet immediately after manufacturing before it can be legally unblocked for sale.
  • Finished Product Shelf-Life Specification: The criteria a product must meet throughout its commercial shelf-life (often allowing for acceptable, minor degradation tolerances compared to the strict release limits).

• Scientifically justified specifications
  

  Development of acceptance criteria, test methods, and release standards for raw materials and finished products.

  • Justification of Specifications Report: A scientific narrative defending the chosen impurities thresholds, pH ranges, or dissolution limits for reviewers.
  • Impurities Profile Document: Complete mapping of organic, inorganic, elemental (ICH Q3D), and residual solvents (ICH Q3C) limits.
  • Reference Standard Characterization Report: The analytical pedigree showing the absolute purity of the baseline chemical standard used to calibrate the testing instruments (e.g., HPLC).

• Statistical acceptance criteria
  

  Data-driven specification limits based on process capability studies and quality risk management.

Process Validation Dossier Support

Preparation of validation protocols and reports covering process reproducibility, batch consistency, in-process controls, and GMP-compliant commercial manufacturing assurance.

• Process Flow Diagram & Process Description

  Translating complex critical process parameters into definitive process flowcharts, guaranteeing scalable, validated formulation manufacturing.

• Scale-Up & Commercialization Dossier Support

  Scientific documentation supporting pilot-to-commercial scale transition with validated reproducibility, process robustness, and commercial manufacturing readiness.

• Finished Product Specification Dossier Support

  Development of final product specifications covering assay, dissolution, physical attributes, microbiological limits, and release criteria.

• International Filing Support

  Technical preparation of dossiers for export registration, market authorization, and compliance submission across global markets.

• Scalability documentation support 

  MFR structured for pilot-to-commercial scale transition, maintaining formulation integrity and reproducibility.

Full Ingredient Transparency & Compliance

• Complete Documentation

  Technical Data Sheets (TDS), Material Safety Data Sheets (MSDS), Certificate of Analysis (COA) for submissions.

• INCI compliance verification

  Alignment with the International Nomenclature of Cosmetic Ingredients to support global cosmetic regulatory requirements.

• Pharmacopeial traceability

  All raw materials linked to USP, EP, BP, or IP monographs, ensuring compendial compliance.

• Quantitative Formula and Composition Statement (QM-CS)

  The definitive master recipe detailing the exact mass, percentage, and function of every active ingredient and excipient, including scientific justifications for any manufacturing overages.

• TSE/BSE Risk Assessment & Origin Declarations

  Certified documentation tracking the biological origin of all raw materials (plant, animal, synthetic, or mineral) to prove zero risk of Transmissible Spongiform Encephalopathy cross-contamination.

• Multi-Compendial Excipient Monograph Compliance Certificates

  Analytical verification showing that every inactive matrix material simultaneously satisfies the rigorous testing criteria of the United States, European, and British Pharmacopeias (USP/EP/BP/IP).

• Allergen and Genetically Modified Organism (GMO) Free Certifications

  Transparent component declarations confirming the absolute absence of major biological allergens or genetically engineered materials within the delivery system matrix